Invitrogen Stock Slides 10 Percent on Missed Q2 Revenues | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Invitrogen were down approximately 9.8 percent, or $6.10, at $56.23 in mid-afternoon trading today after the company reported lower-than-expected revenues for the second quarter, and lowered its financial guidance.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.